Unicycive therapeutics.

UNCY | Complete Unicycive Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Dr. Shalabh Gupta CEO at Unicycive Therapeutics, Inc. 'A physician by training and background - found my passion in bringing new technologies to market - ultimately to help patients, physicians ...Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute …Unicycive Therapeutics has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.Shalabh Gupta, MD, founder, chairman of the board of directors and CEO of Unicycive Therapeutics Inc. Shalabh Gupta, MD, founded Unicycive and has served as ...

Unicycive Therapeutics, Inc. is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead product candidate, Renazorb, is a …

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the ...

Unicycive Therapeutics University of California, Berkeley, Haas School of Business Report this profile About Accomplished pharmaceutical and biotech marketing professional with experience in both ...Jasper Therapeutics’ management team is composed of experienced biopharma industry veterans with extensive track records in drug development and commercialization. With this leadership, we are well positioned to achieve our vision of developing new therapies to treat both chronic and life-threatening mast and stem cell diseases. Learn MoreUNICYCIVE THERAPEUTICS, INC. 2021 OMNIBUS EQUITY INCENTIVE PLAN . Section 1. Purpose of Plan. The name of the Plan is the Unicycive Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan. The purposes of the Plan are to (i) provide an additional incentive to selected employees, directors, independent contractors and consultants of …Nov 14, 2022 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, RENAZORB (lanthanum dioxycarbonate), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia.

Mar 6, 2023 · About Unicycive Therapeutics. Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel investigational phosphate-binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis.

18 Jul 2022 ... Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. ... SOURCE: Unicycive Therapeutics, Inc.

When is Unicycive Therapeutics's earnings date? Unicycive Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, March 29th, 2024 based off last year's report dates. Learn more on UNCY's earnings history.Unicycive Therapeutics is a biopharma company with development programs focused on two kidney dis... Treasure Global Inc. (Nasdaq: TGL) Treasure Global Inc. is a globally recognized e-commerce platform from Malaysia, offering technol...Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational ...US90466Y1038. Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August …Jun 29, 2023 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, lanthanum dioxycarbonate (LDC), is a novel investigational ...

Nov 11, 2021 · Unicycive Therapeutics, Inc. Balance Sheets (in thousands, except for share and per share amounts) As of. As of. December 31, September 30, 2020. 2021 (unaudited) Assets. Current assets: Cash $-$ 18,011. Prepaid related party service fee-58. Deferred offering costs. 200-Prepaid expenses and other current assets. 4. 1,713. Total current assets ... Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational ...Find the latest SEC Filings data for Unicycive Therapeutics, Inc. Common Stock (UNCY) at Nasdaq.com.Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis.About Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, lanthanum dioxycarbonate (LDC), is a novel ...Nov 29, 2023 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational ... Provide the latest market data of Unicycive Therapeutics (UNCY), including prices, candlestick charts of various timeframes, basic information and real-time ...

LOS ALTOS, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...LOS ALTOS, Calif., Nov. 29, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney …

John Townsend, CPA, is Chief Financial Officer at Unicycive Therapeutics Inc. Previously, he has served as Vice President of Finance and Chief Accounting ...Unicycive Therapeutics, Inc. announced that it has signed an agreement issue 130,000 series A convertible preferred shares at an issue price of $1,000 per share for gross proceeds of up to $130 million on March 3, 2023.Shalabh Gupta, MD, founded Unicycive and has served as Chief Executive Officer, President, and director since August 2016. Previously, Dr. Gupta served in various other roles, including founder and Chief Executive Officer of Biocycive Inc.; a commercial strategist at Genentech, Inc.; equity researcher covering US pharmaceutical companies at UBS ...Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update . WATERTOWN, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) Read More . November 3, 2023 . Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b …Dr. Shalabh Gupta, MD, founder, chairman of the board of directors and CEO of Unicycive Therapeutics Inc. Shalabh Gupta, MD, founded Unicycive and has served as Chief Executive Officer, President, and director since August 2016. Previously, Dr. Gupta served in various other roles, including founder and Chief Executive Officer of Biocycive Inc.; a commercial strategist […]Unicycive Therapeutics, Inc. (“the Company”) was incorporated in the State of Delaware on August 18, 2016. The Company was dormant until July 2017 when it began evaluating a number of drug candidates for in-licensing. The Company in-licensed the drug candidate UNI 494 from Sphaera Pharma Pte.Unicycive Therapeutics, Inc. announced that it has signed an agreement issue 130,000 series A convertible preferred shares at an issue price of $1,000 per share for gross proceeds of up to $130 million on March 3, 2023.Inside Unicycive Therapeutics, Inc.'s 10-K Annual Report: Financial - Expense Highlight. These situations, or others associated with COVID-19, could cause delays in our clinical trial plans and could increase expected costs, all of which could have a material adverse effect on our business and financial condition. Financial - Expense …Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being developed for the ...

Jul 20, 2022 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the ...

About Unicycive Therapeutics. Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on …

Oct 23, 2023 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational ... 2 days ago ... Unicycive Therapeutics Inc. The text version of this document is not available. You can access ...Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18 ...6 Sept 2023 ... Sara Kenkare-Mitra, PhD is currently President and Head of Research and Development at Alector where she leads all aspects of the company's R&D ...Sep 29, 2022 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the ... Dr. Shalabh Gupta CEO at Unicycive Therapeutics, Inc. 'A physician by training and background - found my passion in bringing new technologies to market - ultimately to help patients, physicians ...Unicycive Therapeutics, Inc. Monday said it has reached an agreement with the Food and Drug Administration (FDA) on the path to file a New Drug Application for Oxylanthanum Carbonate (OLC) to treat Hyperphosphatemia.Hyperphosphatemia is a condition of having too much phosphorus in the blood, the most common cause of which …Unicycive Therapeutics, Inc. Balance Sheets (in thousands, except for share and per share amounts) As of . As of . December 31, September 30, 2022 . 2023 (Unaudited) AssetsUnicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel investigational phosphate-binding agent being ...Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute …US90466Y1038. Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August …Get the latest Unicycive Therapeutics Inc (UNCY) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

Jun 29, 2023 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, lanthanum dioxycarbonate (LDC), is a novel investigational ... Unicycive Therapeutics. stock was originally listed at a price of $5.85 in Jul 13, 2021. If you had invested in Unicycive Therapeutics stock at $5.85, your return over the last 2 years would have been -91.4%, for an annualized return of -70.68% (not including any dividends or dividend reinvestments).Unicycive Therapeutics, Inc. is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead product candidate, Renazorb, is a novel phosphate binding agent being ...We would like to show you a description here but the site won’t allow us.Instagram:https://instagram. toll brothers raleigh nccoindesbaidu stock forecasticahn enterprises stock dividend The latest Unicycive Therapeutics Inc USD0.001 share price. View recent trades and share price information for Unicycive Therapeutics Inc USD0.001.In health-care professions, “therapeutic use of self” describes the ability of a caregiver to use his or her personality “consciously and in full awareness in an attempt to establish relatedness and to structure nursing interventions,” acco... upxi stockbest veteran mortgage lenders Sep 7, 2022 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the ... is ninja trader a broker Unicycive Therapeutics, Inc. Monday said it has reached an agreement with the Food and Drug Administration (FDA) on the path to file a New Drug Application for Oxylanthanum Carbonate (OLC) to treat Hyperphosphatemia.Hyperphosphatemia is a condition of having too much phosphorus in the blood, the most common cause of which …The Unicycive Therapeutics interview that had been scheduled to air was recorded prior to the company's recent interactions with the U.S. Food and Drug Administration (FDA or Agency) concerning ...About Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia.